Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
- The 1-year graft failure-free survival was 90%, which is clinically meaningful and supports full marketing authorization submission
- Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience
- Submission to EMA for conversion to full marketing authorization planned for Q4 2026
Lund, Sweden, May 27, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post Authorization Efficacy Study (PAES), an open-label confirmatory study investigating one-year graft failure-free survival[*] and patient survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with Idefirix (imlifidase).
